

POAC CRITERIA FOR FUNDED FERRIC CARBOXYMALTOSE INFUSION (CMDHB only)

1. Antenatal Patients

Patient has been diagnosed with iron deficiency anaemia, ferritin is ≤ 20 , and Hb is < 110 g/L and

EITHER

failure of a trial of oral iron therapy due to significant side effects (control minor side effects with symptomatic treatment),

OR

persistent anaemia after 4 weeks despite compliance with oral iron therapy

OR

Rapid correction of anaemia is required

Seek [antenatal clinic advice](#) if:

- Hb < 70 and >34 weeks gestation.
- concern about symptoms.

2. Postnatal Patients

Patient has been diagnosed with iron deficiency anaemia and ferritin ≤ 20 mcg/L and rapid correction of anaemia is required due to one of the following:

- Hb < 90 g/L, or
- HB < 100 g/L with symptoms of anaemia

3. Other Patients

Patient has been diagnosed with iron deficiency anaemia and ferritin ≤ 20 mcg/L

AND has Hb < 100 g/L for women and < 115 g/L for men **AND** one or more of the following:

- failure of a trial of oral iron therapy due to significant side effects (control minor side effects with symptomatic treatment),

OR

- persistent anaemia after 4 weeks despite compliance with oral iron therapy

OR

- Rapid correction of anaemia is required

4. Specialist recommendation option (ferritin level not specified)

- For POAC funding written recommendation from the specialist is required. This can be in the form of a recommendation in a clinic or other letter.
- Alternatively request advice about the use of IV ferric carboxymaltose using the Specialist Advice option on e-referrals.

Criteria:

Patient has been diagnosed with iron deficiency anaemia (HB < 115 female or < 130 Male)

and IV iron infusion is recommended by an internal medicine physician, obstetrician, gynaecologist, or anaesthetist on the grounds that:

- Patient has been compliant with oral iron treatment and treatment has proven ineffective; **or**
- Treatment with oral iron has resulted in dose-limiting intolerance; **or**
- Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease and a trial of oral iron is unlikely to be effective;
or
- Rapid correction of anaemia is required

The specialist's name and the grounds for the recommendation are required for POAC claiming. Note that the grounds for the recommendation will also be required for the PHARMAC Special Authority.

Patients who do not meet the SA criteria for Community funded Ferric Carboxymaltose

POAC will fund the **administration** of IV ferric carboxymaltose if recommended by a specialist even where the special authority criteria for community funding of ferric carboxymaltose are not met. The patient may elect to pay for the ferric carboxymaltose themselves or the specialist may provide a hospital script.